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CASE

SERIES

Methotrexate-induced cutaneous ulceration
in 3 nonpsoriatic patients: Report of a
rare side effect
Hal A. Lewis, BS,a Kathleen M. Nemer, MD,b Rebecca J. Chibnall, MD,b and Amy C. Musiek, MDb
Columbia and St. Louis, Missouri
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INTRODUCTION
Methotrexate (MTX) is a commonly prescribed
medication in the treatment of autoimmune conditions such as rheumatoid arthritis (RA) and psoriasis.
MTX is a folic acid analog and DNA synthesis
inhibitor that competitively inhibits dihydrofolate
reductase. Well-known side effects of MTX include
diarrhea, nausea/vomiting, anorexia, stomatitis, fatigue, and malaise.1 Cutaneous ulceration is a less
commonly described sign of MTX toxicity in patients
with psoriasis. Reported risk factors include relatively high MTX dosage, renal impairment, concurrent nonsteroidal anti-inflammatory drugs, age older
than 55, folate deficiency, low serum albumin, and
drug interactions.2 MTX-induced cutaneous ulceration in nonpsoriatic patients is rare, with the first case
reported in 1998. Since 2011, only 5 cases have been
reported.3 In this case series, we report MTX-induced
cutaneous ulceration in 3 nonpsoriatic patients.

CASE 1
A 52-year-old woman with RA, hypothyroidism,
depression, alcohol abuse, and hepatitis C was
admitted from an outside hospital for right hip pain
and right thigh cellulitis, which developed 3 weeks
after a fall and subsequent pubic rami fracture. On
admission, the patient was found to have pancytopenia, acute kidney injury, and cholestatic transaminitis. MTX level was 0.07 mol/L. She had been
taking 15 mg/wk of MTX for RA for the last 6 months.
The dermatology department was consulted for
superficial ulcerations with crusting and scaling on
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the patient’s hands, digits, arms, legs, and upper
chest of unclear duration (Fig 1). The primary team
was concerned for an atypical infectious process, as
the patient’s cellulitis and skin lesions were not
improving on intravenous vancomycin, meropenem,
and clindamycin.
Punch biopsies for hematoxylin-eosin (H&E)
stain and tissue culture on the left forearm and
right thigh showed focal dermoepidermal separation (Fig 2) and epidermal dysmaturation (Fig 3).
Tissue culture was negative for bacteria, fungus,
and atypical mycobacteria. MTX was stopped, the
hematology department was consulted, and the
patient was administered 1 dose of leucovorin.
Results of a bone marrow biopsy were normal.
Given the negative tissue culture results and
continued cellulitis of the right thigh, the patient
was taken to the operating room for surgical
debridement, which found pyomyositis, fasciitis,
and a hematoma, likely incited from the pelvic
fracture. Intraoperative cultures grew methicillinresistant Staphylococcus aureus. The patient underwent several surgical washouts and debridements of the right thigh with eventual resolution
on 6 weeks of intravenous vancomycin. Blood
counts, creatinine, and liver enzymes all
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Fig 1. Superficial ulcerations with crusting and scaling on the hand, digits, arm, and shin.

Fig 2. Histologic examination of a punch biopsy taken from the left forearm shows a focal
subepidermal split with epidermal necrosis. (H&E; original magnifications: left, 310 and right,
320.)

normalized before discharge, and the patient’s skin
lesions slowly resolved off MTX.

CASE 2
A 56-year-old woman with RA presented to the
hospital for new-onset pancytopenia and rash. She
had been taking 20 mg/wk of MTX for RA for an
unclear length of time. On presentation, there were
necrotic, ulcerated nodules with surrounding erythema on the left second digit at the proximal
interphalangeal joint, right knee, and left dorsal
foot (Fig 4). The patient first noticed these painful,
enlarging lesions 3 months prior after injuring her
fingers on rose thorns in her garden. Before admission, the patient had received courses of amoxicillin,
cephalexin, and sulfamethoxazole/trimethoprim
without improvement.
Laboratory results showed pancytopenia, and an
infectious workup was negative. MTX level was
0.05 mol/L. Two punch biopsies for H&E of the
left knee showed prominent epidermal dysmaturation with nuclear pleomorphic and atypical mitotic
figures (Fig 5). The patient’s MTX was stopped, and
leucovorin was administered, which resulted in
resolution of the cutaneous ulcerations.

CASE 3
A 52-year-old woman with RA, type II diabetes,
hypertension, and hyperlipidemia was admitted to
the medical intensive care unit from an outside
hospital for mouth ulcers, skin rash, fevers, acute
kidney injury, and pancytopenia with an absolute
neutrophil count of 0. On physical examination, the
patient displayed periorbital scaling and thick hemorrhagic crusting of her hard and soft palates. The
patient had thin, crusted ulcerations on the medial
thighs and an eroded plaque underneath the pannus
(Fig 6). At the outside hospital, the patient had
received acyclovir, piperacillin/tazobactam, fluconazole, daptomycin, and anidulafungin.
The patient was unable to provide a history
regarding symptoms or medications, but chart review found she had been taking adalimumab,
leflunomide, and MTX, 25 mg/wk, for at least
2 months before presentation. A viral swab for
herpes simplex virus polymerase chain reaction
was negative. The patient’s mucositis was attributed
to MTX toxicity versus erosive lichen planus as a
paradoxical effect of her recently initiated tumor
necrosis factor inhibitor. MTX level was less than
0.04 mol/L. Punch biopsy findings for H&E of the
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Fig 3. Histologic examination of a punch biopsy taken from the right thigh shows epidermal
dysmaturation and a mixed dermal inflammatory infiltrate with eosinophils. (H&E; original
magnifications: left, 310 and right, 320.)

Fig 4. Necrotic, ulcerated nodules with surrounding erythema on the left second digit at the
proximal interphalangeal joint, right knee, and left dorsal foot.

Fig 5. Histologic examination of a punch biopsy taken from the left knee shows epidermal
dysmaturation with nuclear pleomorphism and atypical mitotic figures. (H&E; original
magnifications: left, 310 and right, 320.)

right thigh displayed epidermal dysmaturation and
dyskeratosis. Because of concern for MTX toxicity,
leucovorin was administered, and MTX, leflunomide, and adalimumab were stopped. The patient’s
mucositis and cutaneous lesions improved
throughout her hospital stay.

DISCUSSION
MTX-induced cutaneous ulceration in psoriatic
patients is a rare side effect of low-dose MTX
treatment and can be an indicator of lifethreatening pancytopenia.4 Ulceration caused by
MTX toxicity in nonpsoriatic patients is even more

rare. In this case series, we report MTX-induced
cutaneous ulceration in 3 nonpsoriatic female patients with rheumatoid arthritis. Similar to previously
reported cases, cutaneous ulceration resolved in our
patients after discontinuation of MTX.1,2,5
The histologic features of MTX-induced cutaneous toxicity are focal dermoepidermal separation
with keratinocyte necrosis and dystrophy, specifically cytologic atypia and dysmaturation.2,6 Biopsies
of lesions from all 3 patients displayed keratinocyte
dystrophy. Case 1 also displayed focal dermoepidermal separation. These pathology findings
confirm that the cutaneous ulcerations were
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Fig 6. Thin, crusted ulcerations on the medial thighs and an eroded plaque underneath the
pannus.

secondary to MTX toxicity and not infection, which
was a suspected cause of ulceration in all 3 cases.
Case 1 was complicated by right thigh pyomyositis;
however, this finding could not explain the cutaneous ulcerations elsewhere on her body.
There is paucity of data on the correlation
between cutaneous toxicity caused by low-dose
MTX treatment (defined as \50 mg/m2) and serum
MTX levels. Serum drug levels are monitored
during high-dose therapy (defined as [500 mg/
m2) for treatment of malignancies and are used to
identify the need for leucovorin rescue. Serum
MTX concentrations suggesting increased risk for
toxicity after high-dose therapy are 10 mol/L after
24 hours, 1 mol/L after 48 hours, and 0.1 mol/L
after 72 hours after MTX administration.7 Each of
our 3 patients received leucovorin rescue and
stopped MTX treatment after toxicity was suspected. This treatment subsequently led to the
resolution of the cutaneous ulcerations; however,
the highest serum MTX level recorded among our
patients was 0.07 mol/L, which is less than the 72hour high-dose toxicity cutoff documented in the
literature. This finding suggests that the serum
drug levels measured during low-dose MTX treatment may be of undetermined significance, and
interpretation of toxicity should be based on
clinical status.
Although cutaneous ulcerations from MTX treatment are not life threatening, the pancytopenia
caused by bone marrow suppression can be fatal.4
The appearance of eroded psoriatic plaques after
low-dose MTX has been documented as an indicator
of impending life-threatening pancytopenia and
warrants the rapid cessation of MTX.4,8 All 3 of our
patients had underlying pancytopenia in addition to
cutaneous findings. Additionally, all 3 patients were
treated with numerous antibiotics before a diagnosis
was rendered. Thus, cutaneous ulceration in nonpsoriatic patients receiving low-dose MTX warrants
drug discontinuation and further hematologic
testing, especially when the infectious workup is
inconclusive.

This case series illustrates 3 examples of MTXinduced cutaneous ulceration in nonpsoriatic patients. All 3 patients were women older than 50 years
taking 15 to 25 mg of MTX per week, who presented
with cutaneous ulcerations of the extremities
mistaken for infection. All 3 patients subsequently
responded to cessation of MTX and initiation of
leucovorin rescue. In addition, our patients all had
MTX serum levels less than 0.07 mol/L and underlying pancytopenia. Therefore, this case series suggests that cutaneous ulceration caused by low-dose
MTX can be suggestive of underlying pancytopenia
and that serum drug levels may be an unreliable
marker of toxicity. This rare cutaneous side effect is
an important forewarning for the more severe
toxicities of MTX treatment.
The authors acknowledge Andras Schaffer, MD, PhD,
for his assistance with the dermatopathology in these
cases.
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